Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's EBIT?
- Axsome Therapeutics (AXSM) reported EBIT of -$63.36M in Q1 2026.
- How has Axsome Therapeutics's EBIT changed year-over-year?
- Axsome Therapeutics's EBIT decreased by 11.2% year-over-year, from -$56.98M to -$63.36M.
- What is the long-term trend for Axsome Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EBIT has grown at a 7.5% compound annual growth rate (CAGR), from -$124.71M to -$166.76M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Axsome Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude